Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Drug Profile

Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Alternative Names: MAGE-A4 SPEAR T-cell therapy; MAGE-A4-SPEAR-T-cell-therapy-Adaptimmune; MAGE-A4ᶜ¹º³²T

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adaptimmune
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Clinical Phase Unknown Haematological malignancies

Most Recent Events

  • 16 Apr 2018 Pharmacodynamics and adverse event data from a preclinical trial in Non-small cell lung cancer released by Adaptimmune Therapeutics
  • 28 Feb 2018 Clinical trials in Haematological malignancies in Canada, USA (IV) (NCT03391791)
  • 28 Feb 2018 Clinical trials in Solid tumours in Canada, USA (IV) (NCT03391791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top